End-stage Renal Disease Clinical Trial
Official title:
Potential Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in End-Stage Renal Disease Patients Undergoing Hemodialysis
The goal of this clinical trial is to learn if Niacin has an effect on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in End-stage renal disease (ESRD) patients undergoing hemodialysis. It will also learn about the safety of Niacin. The main questions it aims to answer are: - Does Niacin lower lipoprotein (a) concentration? - Does Niacin treat hyperphosphatemia in End-stage renal disease (ESRD) patients undergoing hemodialysis? Researchers will compare Niacin to a control group (taking no drug) to see if drug Niacin works to treat hyperphosphatemia and lower lipoprotein (a) concentration. Participants will: - Take drug Niacin or no drug every day for 3 months - Visit the clinic once every 2 weeks for checkups and tests All Patients will be subjected to the following: 1. Informed consent. 2. Demographics and history taking: Using Patient Data sheet. 3. Laboratory evaluation including: Kidney function tests: blood urea,serum creatinine, albumin ,uric acid. Complete blood count (CBC). Lipid profile:Lipoprotein (a),total cholesterol,triglyceride,high density lipoprotein (HDL), low density lipoprotein (LDL). Phosphorous, calcium, sodium, parathyroid hormone (PTH), alkaline phosphatase (ALP). C-reactive protein (CRP).
Chronic kidney disease (CKD) is a clinical syndrome secondary to the definitive change in function and/or structure of the kidney and is characterized by its irreversibility and slow and progressive evolution. CKD is very prevalent in the general adult population .End-stage renal disease (ESRD) was defined as a need for renal replacement therapy, CKD stage G5 (estimated glomerular filtration rate ≤ 15 mL/min per 1.73 m2) .Niacin (generic name of nicotinic acid), also known as vitamin B3, is a naturally occurring water-soluble vitamin that is essential in different biological activities. The active phosphate transport inhibitors are the newest interesting agents in the management of hyperphosphatemia alone or as add-on therapy to the existing phosphate binders. Niacin is one of this novel drug classes that has been demonstrated to show promising therapeutic potential in the treatment of hyperphosphatemia in HD patients.The aim of this study is to evaluate the effect of administration of niacin on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in ESRD patients undergoing hemodialysis.Patients will be randomized into two groups each group includes 25 patients: Control group: 25 patients will receive their standard therapy only. Intervention group (niacin group): 25 patients will receive niacin 500 mg per day with their standard therapy for 3 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04087213 -
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
| Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
| Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
| Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
| Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
| Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
| Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
| Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
| Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
| Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
| Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
| Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
| Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
| Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
| Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
| Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
| Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A |